Clinical Trial

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Business Decision
Summary
This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.
Protocol Amendment History 3 changes
critical Trial terminated 2026-08-04
critical Trial terminated: Business Decision 2026-08-04
minor Completion moved earlier: 2026-03-31 -> 2026-01-09 2026-08-04
Trial Details
NCT Number NCT03843359
Lead Sponsor GlaxoSmithKline
Conditions Neoplasms
Enrollment 97 participants
Start Date 2019-03-12
Primary Completion 2024-04-04 (estimated)
Study Completion 2026-01-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-03